Plecanatide

Immune modulation

Immune balance, inflammation, or resilience support

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Immune / inflammatory modulator
Primary mechanism: Immune or inflammatory pathway modulation
Primary market use: Immune modulation

Pharmacology

Molecular weight (Da): 1681.89
Oral bioavailability: Route-dependent / verify
Half-life: ~2–12 h small-molecule class estimate
Route tags: Oral
Evidence level: MCE product listing / research chemical signal
Clinical status: Research chemical/reference listing
Value-for-money score: 5 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC 50 of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis.

Sources

https://www.medchemexpress.com/plecanatide.html